ArticleBMC plant biology2024
Antiviral properties and molecular docking studies of eco-friendly biosynthesized copper oxide nanoparticles against alfalfa mosaic virus.
Article in BMC plant biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Streptomyces fungicidicus-derived secondary metabolites as an antiviral agent to alleviate zucchini yellow mosaic virus in squash.Scientific reports · 2025Article
- Nanoparticles and Nanocarriers for Managing Plant Viral Diseases.Plants (Basel, Switzerland) · 2025Review
- Advancements in Agricultural Nanotechnology: An Updated Review.Plants (Basel, Switzerland) · 2025Review
- Strategies for plant-virus disease management from gene editing to nanotechnology.Physiology and molecular biology of plants : an international journal of functional plant biology · 2025Review
- Engineering copper and copper-based materials for a post-antibiotic era.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanotechnology has been recognized as a viable technology for enhancing agriculture, particularly in the plant pathogen management area. Alfalfa mosaic virus (AMV) is a global pathogen that affects many plant species, especially economically valuable crops. Currently, there is less data on the interaction of nanoparticles with phytopathogens, particularly viruses. The current study looked into how copper oxide nanoparticles (CuO-NPs)-mediated Haloxylon salicornicum aqueous extract can fight AMV infections on tobacco plants.
resultsScanning electron microscopy (SEM) and transmission electron microscopy (TEM) analyses showed that CuO-NPs have a spherical and hexagonal structure ranging from 20 to 70 nm in size. Fourier transform infrared spectroscopy (FTIR) analysis showed that the produced CuO-NPs have many functional groups and a lot of secondary plant metabolites. Under greenhouse conditions, the foliar application of CuO-NPs (100 ppm) enhanced tobacco growth and decreased viral symptoms. Treatment with CuO-NPs 48 h before (protective treatment) or 48 h after (curative treatment) AMV infection significantly reduced AMV accumulation levels by 97%. Additionally, the levels of total chlorophyll, phenolic, and flavonoid contents, as well as DPPH, exhibited a significant increase in tobacco leaves 30 days after inoculation in comparison to untreated plants. Moreover, considerable differences in levels of different antioxidant enzymes, including SOD, PPO, POX, and CAT, were also observed. On the other hand, the oxidative stress markers (MDA and H
conclusionsThe overall analysis results indicate that the curative treatment is more influential and successful than the protective treatment in combating AMV infection. Consequentially, CuO-NPs could potentially be employed in foliar sprays for the effective and environmentally friendly management of plant virus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.